Cargando…
Fifteen years of irinotecan therapy for pediatric sarcoma: where to next?
Over the past 15 years, irinotecan has emerged as an important agent for treating pediatric sarcoma patients. This review summarizes the activity noted in previous studies, and outlines current issues regarding scheduling, route of administration, and amelioration of side effects. Also discussed are...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4552408/ https://www.ncbi.nlm.nih.gov/pubmed/26322224 http://dx.doi.org/10.1186/s13569-015-0035-x |